Non-invasive prognostic protein biomarker signatures associated with colorectal cancer

EMBO Molecular Medicine

Volumn 7, Issue 9, 2015, Pages 1153-1165

  Surinova, Silvia ^a,h   Radová, Lenka ^b,i   Choi, Meena ^c   Srovnal, Josef ^b   Brenner, Hermann ^d   Vitek, Olga ^c,e,f   Hajdúch, Marián ^b   Aebersold, Ruedi ^a,g  

^a ETH ZURICH   (Switzerland)

^b PALACKÝ UNIVERSITY   (Czech Republic)

^c PURDUE UNIVERSITY   (United States)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e Purdue University   (United States)

^f Northeastern University   (United States)

^g UNIVERSITY OF ZURICH   (Switzerland)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁱ MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Colorectal cancer; Prognostic protein biomarker; Targeted proteomics

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENT FACTOR H; GLYCOPROTEIN; HERMES ANTIGEN; HLA A ANTIGEN; MESSENGER RNA; VASCULAR ENDOTHELIAL CADHERIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; METASTASIS; NON INVASIVE MEASUREMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SURVIVAL PREDICTION; TRANSCRIPTION REGULATION; TUMOR LOCALIZATION; BLOOD; CHEMISTRY; COLORECTAL NEOPLASMS; LABORATORY TEST; PATHOLOGY; PLASMA; PROCEDURES; PROGNOSIS;

BIOMARKERS, TUMOR; CLINICAL LABORATORY TECHNIQUES; COLORECTAL NEOPLASMS; HUMANS; PLASMA; PROGNOSIS; PROTEOMICS;

EID: 84940790564     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.15252/emmm.201404874     Document Type: Article

References (28)

1. Brenner H, Kloor M, Pox CP (2014) Colorectal cancer. Lancet 383: 1490-1502
2. Cancer Genome Atlas N (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487: 330-337
3. Chandler I, Houlston RS (2008) Interobserver agreement in grading of colorectal cancers-findings from a nationwide web-based survey of histopathologists. Histopathology 52: 494-499
4. Choi M, Chang CY, Clough T, Broudy D, Killeen T, Maclean B, Vitek O (2014) MSstats: an R package for statistical analysis of quantitative mass spectrometry-based proteomic experiments. Bioinformatics 30: 2524-2526
5. Cui TT, Chen Y, Knosel T, Yang LL, Zoller K, Galler K, Berndt A, Mihlan M, Zipfel PF, Petersen I (2011) Human complement factor H is a novel diagnostic marker for lung adenocarcinoma. Int J Oncol 39: 161-168
6. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling N (2010) Colorectal cancer. Lancet 375: 1030-1047
7. De Sousa EMF, Colak S, Buikhuisen J, Koster J, Cameron K, de Jong JH, Tuynman JB, Prasetyanti PR, Fessler E, van den Bergh SP et al (2011) Methylation of cancer-stem-cell-associated Wnt target genes predicts poor prognosis in colorectal cancer patients. Cell Stem Cell 9: 476-485
8. De Sousa EMF, Wang X, Jansen M, Fessler E, Trinh A, de Rooij LP, de Jong JH, de Boer OJ, van Leersum R, Bijlsma MF et al (2013) Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med 19: 614-618
9. Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, Lamerz R, Peltomaki P, Sturgeon C, Topolcan O (2007) Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 43: 1348-1360
10. Farrah T, Deutsch EW, Kreisberg R, Sun Z, Campbell DS, Mendoza L, Kusebauch U, Brusniak MY, Hüttenhain R, Schiess R et al (2012) PASSEL: the peptideAtlas SRMexperiment library. Proteomics 12: 1170-1175
11. Fawcett T (2006) An introduction to ROC analysis. Pattern Recogn Lett 27: 861-874
12. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. New Engl J Med 366: 883-892
13. Heagerty PJ, Zheng YY (2005) Survival model predictive accuracy and ROC curves. Biometrics 61: 92-105
14. Huh JW, Kim HR, Kim YJ, Lee JH, Park YS, Cho SH, Joo JK (2009) Expression of standard CD44 in human colorectal carcinoma: association with prognosis. Pathol Int 59: 241-246
15. Hüttenhain R, Surinova S, Ossola R, Sun Z, Campbell D, Cerciello F, Schiess R, Bausch-Fluck D, Rosenberger G, Chen J et al (2013) N-glycoprotein SRMAtlas: a resource of mass spectrometric assays for N-glycosites enabling consistent and multiplexed protein quantification for clinical applications. Mol Cell Proteomics 12: 1005-1016
16. Jorissen RN, Lipton L, Gibbs P, Chapman M, Desai J, Jones IT, Yeatman TJ, East P, Tomlinson IPM, Verspaget HW et al (2008) DNA copy-number alterations underlie gene expression differences between microsatellite stable and unstable colorectal cancers. Clin Cancer Res 14: 8061-8069
17. Jorissen RN, Gibbs P, Christie M, Prakash S, Lipton L, Desai J, Kerr D, Aaltonen LA, Arango D, Kruhoffer M et al (2009) Metastasis-associated gene expression changes predict poor outcomes in patients with dukes stage B and C colorectal cancer. Clin Cancer Res 15: 7642-7651
18. Li FY, Lai MD (2009) Colorectal cancer, one entity or three. J Zhejiang Univ Sci B 10: 219-229
19. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC (2006) ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24: 5313-5327
20. Ludwig JA, Weinstein JN (2005) Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 5: 845-856
21. Pesson M, Volant A, Uguen A, Trillet K, De La Grange P, Aubry M, Daoulas M, Robaszkiewicz M, Le Gac G, Morel A et al (2014) A gene expression and pre-mRNA splicing signature that marks the adenoma-adenocarcinoma progression in colorectal cancer. PLoS ONE 9: e87761
22. Riihila PM, Nissinen LM, Ala-aho R, Kallajoki M, Grenman R, Meri S, Peltonen S, Peltonen J, Kahari VM (2014) Complement factor H: a biomarker for progression of cutaneous squamous cell carcinoma. J Invest Dermatol 134: 498-506
23. Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, Ostos LCG, Lannon WA, Grotzinger C, Del Rio M et al (2013) A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med 19: 619-625
24. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S et al (2012) Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62: 220-241
25. Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, Jiang A, Lu P, Johnson JC, Schmidt C, Bailey CE et al (2010) Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology 138: 958-968
26. Surinova S, Schiess R, Hüttenhain R, Cerciello F, Wollscheid B, Aebersold R (2011) On the development of plasma protein biomarkers. J Proteome Res 10: 5-16
27. Surinova S, Choi M, Tao S, Schüffler PJ, Chang CY, Clough T, Vysloužil K, Khoylou M, Srovnal J, Liu Y et al (2015) Prediction of colorectal cancer diagnosis based on circulating plasma proteins. EMBO Mol Med 7: 1166-1178
28. Zhang B, Wang J, Wang X, Zhu J, Liu Q, Shi Z, Chambers MC, Zimmerman LJ, Shaddox KF, Kim S et al (2014) Proteogenomic characterization of human colon and rectal cancer. Nature 513: 382-387